Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company. Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation, is based in NASHVILLE, Tenn.
| Revenue (Most Recent Fiscal Year) | $1.88M |
| Net Income (Most Recent Fiscal Year) | $-60.66M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 40.41 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 156.54 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1489.71% |
| Net Margin (Trailing 12 Months) | -1489.71% |
| Return on Equity (Trailing 12 Months) | -983.30% |
| Return on Assets (Trailing 12 Months) | -39.81% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.04 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.93 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 4.32 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.70 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.30 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.45 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.47 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 28.62M |
| Free Float | 28.03M |
| Market Capitalization | $172.01M |
| Average Volume (Last 20 Days) | 0.08M |
| Beta (Past 60 Months) | 1.33 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.05% |
| Percentage Held By Institutions (Latest 13F Reports) | 55.35% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |